Brain and Cognition Discovery Foundation (BCDF)
@bcdfoundation
Developing novel innovative strategies capable of augmenting best practices in today's healthcare ecosystem.
ID: 727990387739078656
https://linktr.ee/bcdfoundation 04-05-2016 22:36:48
4,4K Tweet
405 Followers
224 Following
The KOASTAL-2 study is looking at Navacaprant, a new treatment for depression and anhedonia in adults between 18 to 65 years old. If you or anyone that you know is interested in the KOASTAL-2 study, please reach out to us at: [email protected]
The BCDF is recruiting participants for KOASTAL-2, a clinical study evaluating a new treatment called Navacaprant for the treatment of depression and anhedonia. Have questions about the study? Feel free to reach out to us at [email protected]
KOASTAL-2 is evaluating Navacaprant for the treatment of depressive symptoms and anhedonia (reduced joy or pleasure in activities) in adults with major depressive disorder. Interested or have questions about the study? Feel free to reach out to us at [email protected]
The KOASTAL-2 study is evaluating a new treatment called Navacaprant on depressive symptoms and anhedonia in adults with major depressive disorder. To learn more, visit: bcdfoundation.ca/k-opioid-antag… Have questions? Email us at: [email protected]
The KOASTAL-2 study is evaluating Navacaprant as a new treatment for adults with major depressive disorder. To learn more about KOASTAL-2, visit bcdfoundation.ca/k-opioid-antag… Have questions about KOASTAL-2? Reach out to us at [email protected]
The KOASTAL-2 study is evaluating Navacaprant as a treatment for depressive symptoms and anhedonia in adults with major depressive disorder. Want to know more? Visit our website at bcdfoundation.ca/k-opioid-antag… Have questions? Reach out to us at [email protected]
The KOASTAL-2 study is looking at Navacaprant as a treatment for depressive symptoms and anhedonia in adults with major depressive disorder. To learn more about KOASTAL-2, visit bcdfoundation.ca/k-opioid-antag… Have questions about the study? Reach out to us at [email protected]
KOASTAL-2 is evaluating Navacaprant as a new treatment for depressive symptoms and anhedonia in adults with major depressive disorder. To learn more about the study, visit our website at bcdfoundation.ca/k-opioid-antag… Have any questions? Reach out to us at [email protected]
The KOASTAL-2 study is investigating Navacaprant for the treatment of depression and anhedonia (reduced joy or pleasure in activities) in adults. To learn more, visit our website at bcdfoundation.ca/k-opioid-antag… Have questions? Feel free to email us at [email protected]
The KOASTAL-2 study is evaluating a once-daily treatment called Navacaprant for its use in adults with major depressive disorder. To learn more about KOASTAL-2, visit bcdfoundation.ca/k-opioid-antag… Have questions about the study? Reach out to us at [email protected]
The KOASTAL-2 study is evaluating the use of a once-daily treatment called Navacaprant in adults with major depressive disorder. To learn more about the study, visit our website at: bcdfoundation.ca/k-opioid-antag… Have any questions? Feel free to email us at [email protected]
The KOASTAL-2 study is taking place in Toronto/Mississauga and aims to evaluate a once-daily treatment called Navacaprant for adults with depression. To learn more about the study, visit: bcdfoundation.ca/k-opioid-antag… Have any questions? Please email us at [email protected]
KOASTAL-2 is investigating a once-daily medicine called Navacaprant for the treatment of depressive symptoms and anhedonia in adults with major depressive disorder. To learn more, visit: bcdfoundation.ca/k-opioid-antag… For inquiries, please email us at [email protected]
KOASTAL-2 is a clinical study taking place in Toronto and Mississauga. This study aims to evaluate a new once-daily treatment called Navacaprant for adults with major depressive disorder. To participate or learn more, please reach out to us at [email protected]
The KOASTAL-2 study is evaluating a new once-daily treatment called Navacaprant on depressive symptoms and anhedonia in adults with major depressive disorder. To learn more about this study, visit: bcdfoundation.ca/k-opioid-antag… Have any questions? Email us at: [email protected]
A new once-daily treatment called Navacaprant is being evaluated in adults (18 - 65 years old) with major depressive disorder. For more information, visit our website at: bcdfoundation.ca/k-opioid-antag… Have any questions? Please reach out to us at [email protected]
The KOASTAL-2 study taking place in Toronto and Mississauga is assessing Navacaprant for the treatment of depressive symptoms and anhedonia in adults (18 to 65 years old) with major depressive disorder. Have questions? If so, please reach out to us at [email protected]
KOASTAL-2 is assessing a new once-daily treatment called Navacaprant for depression and anhedonia in adults! Individuals diagnosed with major depressive disorder and are 18 to 65 years old may be eligible for this study. Interested? Email us at [email protected]
The BCDF is recruiting participants for KOASTAL-2, a clinical study happening in Toronto and Mississauga. Individuals diagnosed with major depressive disorder and are 18 to 65 years old may be eligible for this study. Reach out to us at [email protected] to learn more!
